Clinical Trial

Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced adenocarcinoma of gastric/esophagogastric junction
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-06.
Trial Details
NCT Number NCT07406984
Lead Sponsor Beijing Immunochina Medical Science & Technology Co., Ltd.
Collaborators: Peking University Cancer Hospital & Institute
Conditions Adenocarcinoma of Gastric, Adenocarcinoma of Esophagogastric Junction
Enrollment 18 participants
Start Date 2026-03-05
Primary Completion 2027-05-05 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-13